NASDAQ:VTGN VistaGen Therapeutics (VTGN) Stock Price, News & Analysis $3.93 -0.10 (-2.56%) As of 10:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About VistaGen Therapeutics Stock (NASDAQ:VTGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VistaGen Therapeutics alerts:Sign Up Key Stats Today's Range$4.00▼$4.1050-Day Range$2.73▼$4.2152-Week Range$1.90▼$4.39Volume55,269 shsAverage Volume304,592 shsMarket Capitalization$120.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview VistaGen Therapeutics, Inc. (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions. The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain. VistaGen also develops PH-10, a topical neuroactive small molecule in clinical development for psoriasis and atopic dermatitis. To broaden its development reach, VistaGen has entered strategic partnerships, including a licensing agreement with Yuhan Corporation for AV-101 in South Korea, and continues to advance its clinical and regulatory strategy primarily in North America and Asia. VistaGen’s proprietary Human Clinical Drug Rescue and ReRationalization platform employs patient-derived pluripotent stem cell–derived neural and cardiac cells to predict clinical efficacy and safety, reduce late-stage development risk and complement traditional preclinical models. This platform supports both in-house pipeline programs and collaborative research initiatives. Leading the company is President and Chief Executive Officer Shawn K. Singh, who has overseen VistaGen’s research and corporate development efforts since joining in 2014 and remains committed to translating innovative science into new therapeutic options for underserved patient populations.AI Generated. May Contain Errors. Read More VistaGen Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreVTGN MarketRank™: VistaGen Therapeutics scored higher than 21% of companies evaluated by MarketBeat, and ranked 866th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for VistaGen Therapeutics.Read more about VistaGen Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for VistaGen Therapeutics are expected to grow in the coming year, from ($1.77) to ($1.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VistaGen Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VistaGen Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVistaGen Therapeutics has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about VistaGen Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.18% of the float of VistaGen Therapeutics has been sold short.Short Interest Ratio / Days to CoverVistaGen Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VistaGen Therapeutics has recently increased by 22.57%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVistaGen Therapeutics does not currently pay a dividend.Dividend GrowthVistaGen Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.18% of the float of VistaGen Therapeutics has been sold short.Short Interest Ratio / Days to CoverVistaGen Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VistaGen Therapeutics has recently increased by 22.57%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.83 News SentimentVistaGen Therapeutics has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for VistaGen Therapeutics this week, compared to 1 article on an average week.Search Interest18 people have searched for VTGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows9 people have added VistaGen Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, VistaGen Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.85% of the stock of VistaGen Therapeutics is held by insiders.Percentage Held by Institutions78.39% of the stock of VistaGen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about VistaGen Therapeutics' insider trading history. Receive VTGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VTGN Stock News HeadlinesIs Vistagen Therapeutics (NASDAQ:VTGN) In A Good Position To Invest In Growth?September 27, 2025 | finance.yahoo.comJanus Henderson Just Took a 13.6% Stake in Vistagen. Should You Buy VTGN Stock Now?September 26, 2025 | msn.comThe 7 Warning Signals Flashing Red Right NowA free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. Right now, all seven are flashing red simultaneously for the first time since 2007. These aren't the signals you'll see on CNBC.October 13 at 2:00 AM | American Alternative (Ad)Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy SummitSeptember 9, 2025 | businesswire.comVistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety TrialSeptember 2, 2025 | sg.finance.yahoo.comWhile institutions invested in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) benefited from last week's 11% gain, retail investors stood to gain the mostAugust 17, 2025 | finance.yahoo.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call TranscriptAugust 12, 2025 | msn.comVistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ...August 8, 2025 | finance.yahoo.comSee More Headlines VTGN Stock Analysis - Frequently Asked Questions How have VTGN shares performed this year? VistaGen Therapeutics' stock was trading at $2.95 on January 1st, 2025. Since then, VTGN stock has increased by 33.1% and is now trading at $3.9270. How were VistaGen Therapeutics' earnings last quarter? VistaGen Therapeutics, Inc. (NASDAQ:VTGN) posted its quarterly earnings data on Thursday, August, 7th. The company reported ($0.47) EPS for the quarter, hitting the consensus estimate of ($0.47). The company had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.22 million. Read the conference call transcript. When did VistaGen Therapeutics' stock split? Shares of VistaGen Therapeutics reverse split before market open on Wednesday, June 7th 2023.The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of VistaGen Therapeutics? Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VistaGen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that VistaGen Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/07/2025Today10/13/2025Next Earnings (Estimated)11/06/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VTGN CIK1411685 Webwww.vistagen.com Phone(650) 577-3600Fax888-482-2602Employees40Year Founded1998Profitability EPS (Trailing Twelve Months)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.42 million Net MarginsN/A Pretax Margin-8,633.59% Return on Equity-74.06% Return on Assets-64.10% Debt Debt-to-Equity RatioN/A Current Ratio5.98 Quick Ratio5.98 Sales & Book Value Annual Sales$646 thousand Price / Sales191.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.44 per share Price / Book1.65Miscellaneous Outstanding Shares30,680,000Free Float29,806,000Market Cap$123.64 million OptionableOptionable Beta0.55 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:VTGN) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VistaGen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.